Merck Reports Phase 2b Results For Efinopegdutide In MASH, Meaningful Improvements Were Observed In Liver Fibrosis Without Worsening Of Steatohepatitis, A Key Secondary Histologic Endpoint; Results Presented At The Liver Meeting And Published In The Lancet

Efinopegdutide demonstrated a statistically significant greater proportion of participants achieved MASH resolution without worsening of fibrosis versus placebo at 52 weeks

Meaningful improvements were observed in liver fibrosis without worsening of steatohepatitis, a key secondary histologic endpoint

Results presented at The Liver Meeting® and published in The Lancet

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company’s Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide (4 mg, 7 mg and 10 mg), an investigational injectable GLP-1/glucagon receptor co-agonist, versus placebo for the treatment of adults with MASH and stage F2 or F3 liver fibrosis. The findings were presented during a late-breaking abstract session at The Liver Meeting (TLM), being held in Denver, Colo., and simultaneously published in The Lancet.